Effect of neoadjuvant therapy on tumor tissue PD-L1 and VISTA expression levels in non-small-cell lung cancer

PD-L1 and VISTA are important checkpoint control stations and play an immunomodulatory role in patients with non-small-cell lung cancer. The expression levels of PD-L1 and VISTA between pre- and post-treatment tumor tissue were compared. While PD-L1 expression was >1% in 35% of patients before ne...

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2022-10, Vol.14 (14), p.1121-1131
Main Authors: Akdoğan, Orhun, Sütcüoğlu, Osman, Öğüt, Betül, Akyürek, Nalan, Özdemir, Nuriye, Özet, Ahmet, Yazıcı, Ozan
Format: Article
Language:English
Subjects:
biomarker
chemotherapy
immunotherapy
molecular oncology
PD-L1
radiotherapy
VISTA
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PD-L1 and VISTA are important checkpoint control stations and play an immunomodulatory role in patients with non-small-cell lung cancer. The expression levels of PD-L1 and VISTA between pre- and post-treatment tumor tissue were compared. While PD-L1 expression was >1% in 35% of patients before neoadjuvant therapy, PD-L1 expression was >1% in 65% of patients after treatment (p = 0.004). VISTA expression was >1% in 41% of patients before treatment, and this rate was 65% after treatment (p = 0.025). Chemotherapy and chemoradiotherapy can be used as immunizers by increasing PD-L1 and VISTA expression levels.
ISSN:1750-743X
1750-7448
DOI:10.2217/imt-2021-0338